Abstract 1738P
Background
Tobacco remains the leading preventable risk factor for cancer in the world. Although the prevalence of tobacco use has a decreasing trend in most European countries, the availability of new smoking devices is causing an increase in smokers, especially among the younger population. Several studies have confirmed the relationship between this increase and indirect or covert advertising, carried out on social media and VOD platforms, through product placement, etc. This study aims to measure the impact of tobacco and new smoking devices in these digital spaces on the young Spanish population; and how this impact is related to increased consumption.
Methods
A survey has been conducted on the young Spanish population (aged between 16 to 21 years old) using a representative online panel of this population. The final sample obtained was 1730 interviews, and the data collection was conducted in December 2022. A questionnaire with an average duration of 10 minutes was administered, in which questions related to tobacco and new smoking devices use, and the recall of having seen content related to traditional tobacco and new smoking devices were collected. Descriptive and logistic regression analyses have been performed, taking the habitual consumption (last month) of tobacco and new smoking device as dependent variables.
Results
82.5% of young people remember having had some impact related to traditional tobacco, and 83% with new smoking forms. Among young people who have had this impact, there are twice as many smokers (53.1%) as among those who have not (24.5%). Having seen someone smoking cigarettes on these platforms (AOR 1.56), cigarette product placement (AOR 1.71), or recalling e-cigarette brands (AOR 1.58) are the variables that most increase the risk of regularly consuming traditional cigarettes. The same happens in the risk of habitual consumption of new devices, with the recall of having seen specific brands or logos taking special relevance (AOR 2.47).
Conclusions
There is a correlation between the recall of these types of consumption and the regular consumption of tobacco or new forms of smoking. It is necessary to continue researching this avenue of normalization of consumption and to ensure the protection of young people from the promotion of new devices.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Asociación Española Contra el Cáncer.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1902P - Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC)
Presenter: Audreylie Lemelin
Session: Poster session 23
1903P - Tumor response by baseline metastases in patients (pts) with renal cell carcinoma (RCC) treated with lenvatinib (L) plus pembrolizumab (P) vs sunitinib (S): Post hoc analysis of the CLEAR trial
Presenter: Viktor Gruenwald
Session: Poster session 23
1904P - Treatment options and outcome of metastatic renal cell carcinoma patients with brain or bone metastases: A real-world evidence from a German retrospective multi-center analysis
Presenter: Pia Paffenholz
Session: Poster session 23
1905P - Heterogeneity in tertiary lymphoid structures predicts the distinct prognosis and immune microenvironment of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster session 23
1906P - Metastasized non-clear cell renal cell carcinoma: Which entities are dangerous? Results learned from reference pathology of the SuniForecast study
Presenter: Arndt Hartmann
Session: Poster session 23
1907P - Multi-omics mapping positions antigenic myeloid-T cell crosstalk at the core of advanced renal cell carcinoma (aRCC) response to immune checkpoint blockade (ICB)
Presenter: Lisa Kinget
Session: Poster session 23
1908P - Utility of circulating tumor (ct)DNA testing for molecular residual disease (MRD) detection and treatment response monitoring in patients (pts) with renal cell carcinoma (RCC)
Presenter: Michael Smigelski
Session: Poster session 23
1909P - Baseline cytokine levels according to the line of treatment in patients with metastatic clear cell renal cell carcinoma treated with nivolumab: NIVOREN GETUG-AFU 26 translational study
Presenter: Larissa Rainho
Session: Poster session 23
1910P - Evaluation of a genome-wide methylome enrichment platform for circulating tumor DNA quantification and prognostic performance in renal cell carcinoma (RCC)
Presenter: Brian Rini
Session: Poster session 23
1911P - Effect of VHL mutations on efficacy of immune checkpoint inhibitors in renal cell carcinoma
Presenter: Guojie Yu
Session: Poster session 23